Involved site radiotherapy

RADIATION2 trials

Sponsors

University College, London, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Early-stageExtranodal NK-T-Cell LymphomaHigh-Risk CancerHodgkin Lymphoma

Phase 2

A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)

CompletedNCT05254899

Cancer Institute and Hospital, Chinese Academy of Medical SciencesEarly-stage, Extranodal NK-T-Cell Lymphoma, High-Risk Cancer

Start: 2021-11-10End: 2026-03-31Updated: 2026-08-20

Phase 3

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

RecruitingNCT04685616

University College, LondonHodgkin Lymphoma

Start: 2022-04-14End: 2032-09-01Target: 1042Updated: 2026-07-08

Related Papers

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study

Blood Advances2025-01-073 citations